PT  - JOURNAL ARTICLE
AU  - Sun, James
AU  - Barth, Katrina
AU  - Qiao, Shaoyu
AU  - Chiang, Chia-Han
AU  - Wang, Charles
AU  - Rahimpour, Shervin
AU  - Trumpis, Michael
AU  - Duraivel, Suseendrakumar
AU  - Dubey, Agrita
AU  - Wingel, Katie E.
AU  - Rachinskiy, Iakov
AU  - Voinas, Alex S.
AU  - Ferrentino, Breonna
AU  - Southwell, Derek G.
AU  - Haglund, Michael M.
AU  - Friedman, Allan H.
AU  - Lad, Shivanand P.
AU  - Doyle, Werner K.
AU  - Solzbacher, Florian
AU  - Cogan, Gregory
AU  - Sinha, Saurabh R.
AU  - Devore, Sasha
AU  - Devinsky, Orrin
AU  - Friedman, Daniel
AU  - Pesaran, Bijan
AU  - Viventi, Jonathan
TI  - Intraoperative microseizure detection using a high-density micro-electrocorticography electrode array
AID  - 10.1101/2021.09.13.21263449
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.13.21263449
4099  - http://medrxiv.org/content/early/2021/09/15/2021.09.13.21263449.short
4100  - http://medrxiv.org/content/early/2021/09/15/2021.09.13.21263449.full
AB  - One-third of epilepsy patients suffer from medication-resistant seizures. While surgery to remove epileptogenic tissue helps some patients, 30–70% of patients continue to experience seizures following resection. Surgical outcomes may be improved with more accurate localization of epileptogenic tissue. We have previously developed novel thin-film, subdural electrode arrays with hundreds of microelectrodes over a 100–1,000 mm2 area to enable high-resolution mapping of neural activity. Here we used these high-density arrays to study microscale properties of human epileptiform activity. We performed intraoperative micro-electrocorticographic recordings within epileptic cortex (the site of seizure onset and early spread) in nine patients with epilepsy. In two of these patients, we obtained recordings from cortical areas distal to the epileptic cortex. Additionally, we recorded from two non-epileptic patients with movement disorders undergoing deep brain stimulator implantation as non-epileptic tissue controls. A board-certified epileptologist identified microseizures, which resembled electrographic seizures normally observed with clinical macroelectrodes. Epileptic cortex exhibited a significantly higher microseizure rate (2.01 events/min) than non-epileptic cortex (0.01 events/min; permutation test, P=0.0068). Using spatial averaging to simulate recordings from larger electrode contacts, we found that the number of detected microseizures decreased rapidly with increasing contact diameter and decreasing contact density. In cases in which microseizures were spatially distributed across multiple channels, the approximate onset region was identified. Our results suggest that micro-electrocorticographic electrode arrays with a high density of contacts and large coverage are essential for capturing microseizures in epilepsy patients and may be beneficial for localizing epileptogenic tissue to plan surgery or target brain stimulation.Competing Interest StatementParts of the technology described here are patent pending under 'Electroencephalography (EEG) Electrode Arrays and Related Methods of Use' U.S. Patent Application # PCT/US2020/051400. F. Solzbacher declares financial interest in Blackrock Microsystems LLC and Sentiomed, Inc., managed by University of Utah's COI management. W. Doyle and D. Friedman declare financial interest in Neuroview Technology overseen by NYU Grossman School of Medicine's COI management. D. Friedman also receives salary support for consulting and clinical trial related activities performed on behalf of The Epilepsy Study Consortium, a non-profit organization. Dr. Friedman receives no personal income for these activities. NYU receives a fixed amount from the Epilepsy Study Consortium towards Dr. Friedman's salary. Within the past two years, The Epilepsy Study Consortium received payments for research services performed by Dr. Friedman from Alterity, Baergic, Biogen, BioXcell, Cerevel, Cerebral, Jannsen, Lundbeck, Neurocrine, SK Life Science, and Xenon. Dr. Friedman has also served as a paid consultant for Neurelis Pharmaceuticals and Receptor Life Sciences. OD has equity and/or compensation from Privateer Holdings, Tilray, Receptor Life Sciences, Qstate Biosciences, Tevard, Empatica, Engage, Egg Rock/Papa & Barkley, Rettco, SilverSpike, and California Cannabis Enterprises. He has received consulting fees from GW Pharma, Cavion, and Zogenix. Saurabh R. Sinha has received salary/research support for clinical trials from Eisai, Monteris, Neuropace, UCB, and Sunovion. Within the past two years, Dr. Sinha has received payments for consulting/advisory boards from Acquestive, Basilea, Blackthorn Therapeutics, LivaNova, Monteris, Neuropace, SK Lifesciences, and UCB.Funding StatementJ.S. receives support from the NIH (T32 GM136573), the Vilcek Fellowship, and the American Epilepsy Society. D.F. receives support from the NIH (R01 NS06209207, NIH R01 NS109367, CDC U48DP006396-01SIP 19-003) and Epitel. O.D. receives support from the NIH (R01 MH107396, U01 NS099705, R01 MH111417, U01 NS090415, R01 MH116978, R01 HL151490), Tuberous Sclerosis Alliance, Epilepsy Foundation of American, and the National Science Foundation. W.D. receives support from the NIH (R01 NS062092, R01 MH116978). S.D. receives support from the NIH (RF1 MH116978, R01 MH111417, R01 NS062092), Office of Naval Research, and the Templeton World Charity Foundation. BP receives support from NIH U01 NS099697, U01 NS099577, U01 NS103518, U01 NS122123, R01 NS104923, ARO 68984-CS-MUR, NSF IOS-1557886 and NSF IIS-2113271. J.V. receives support from Grant #DoD EP200077, NIH U01 NS099697, NIH 1UG3NS120172, NIH 1U01NS123668, NSF CBET-1752274, and NIH CTSA grant UL1TR002553. D.S. receives support from the NIH (K12 NS080223) and the Esther A. & Joseph Klingenstein Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from all patients in accordance with the Institutional Review Boards at New York University Langone Health and the Duke University Health System.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData obtained in this study are available upon request. Please contact the corresponding authors with any inquiries.DBSdeep brain stimulation;ECepileptic cortex;ECoGelectrocorticography;EZepileptogenic zone;IRBInstitutional Review Board;ISOInternational Organization of Standardization;LCPliquid crystal polymer;LCP-TFliquid crystal polymer thin-film;LFPlocal field potential;LLline length;PEDOT:PSSpoly(3,4-ethylenedioxythiophene) polystyrene sulfonate;PtIrplatinum-iridium;RNSresponsive neurostimulation;sEEGstereo-electroencephalography;TFthin film;VNSvagal nerve stimulation;µECoGmicro-electrocorticography;µHDMImicro high-definition multimedia interface